21193-61-3

Upstream product

• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 60343-84-2 2',3',5'-tri-O-acetyltubercidin 
• 952429-12-8 5-bromo-4-chloro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 952429-11-7 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate 

Downstream Products

• 69-33-0 tubercidin 
• 40725-89-1 4-amino-N7-(3'-deoxy-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 
• 1428254-19-6 (2R,3R,4R,5R)-2-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(chloromethyl)tetra-hydrofuran-3,4-diol 

Relevant academic research and scientific papers

Chemical synthesis and biological activity of novel brominated 7-deazaadenosine-3′,5′-cyclic monophosphate derivatives

Synthetic derivatives of cyclic adenosine monophosphate, such as halogenated or other more hydrophobic analogs, are widely used compounds, to investigate diverse signal transduction pathways of eukaryotic cells. This inspired us to develop cyclic nucleoti

A containing spiro group of the pyrrolo [2, 3 - d] pyrimidine compound and its preparation method

The present invention provides a formula (I) of the formula (II) is shown including volute group of the pyrrolo [2, 3 - d] pyrimidine compounds and their pharmaceutically acceptable salt, and method of preparation and application. Compounds of this class

NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS

The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASE 5 (PRMT5)

The disclosure is directed to compounds of Formula I, Formula II, and Formula III [Formulas should be inserted here]. Methods of their use and preparation are also described.

NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Synthesis of 8-(1,2,3-triazol-1-yl)-7-deazapurine nucleosides by azide–alkyne click reactions and direct C[sbnd]H bond functionalization

Treatment of toyocamycin or sangivamycin with 1,3-dibromo-5,5-dimethylhydantoin in MeOH (rt/30?min) gave 8-bromotoyocamycin and 8-bromosangivamycin in good yields. Nucleophilic aromatic substitution of 8-bromotoyocamycin with sodium azide provided novel 8

Bromo-deaza-SAH: A potent and selective DOT1L inhibitor

Chemical inhibition of proteins involved in chromatin-mediated signaling is an emerging strategy to control chromatin compaction with the aim to reprogram expression networks to alter disease states. Protein methyltransferases constitute one of the protei

7-Functionalized 7-deazapurine β-d and β-l-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo[2,3-d]pyrimidines with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-d or β-l-ribofuranose

Several 7-functionalized 7-deazapurine ribonucleosides were prepared. Glycosylation of 7-halogenated 6-chloro-7-deazapurines with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-d-ribofuranose or 1-O-acetyl-2,3,5-tri-O-benzoyl-β-l-ribofuranose gave the protected β-d-nuc